MRPL50

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, MRPL50 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MRPL50 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MRPL50 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MRPL50 expression acts as an unfavorable survival marker.

LUAD and KICH are the cancer types where MRPL50 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
LUADOSMedianIII,IV0.2230.677.00615view →
KICHDFSMedianAll0.1020.848.00413view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MRPL50–LUAD (OS)

Kaplan–Meier survival curve for MRPL50 mutant vs wild-type samples in LUAD.

Open the LUAD breakdown →

Exploration